Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia.
Arteriosclerosis
/ genetics
Graft Rejection
/ prevention & control
Hematopoietic Stem Cell Transplantation
Humans
Immunologic Deficiency Syndromes
/ therapy
Kidney
/ physiology
Kidney Transplantation
/ adverse effects
Nephrotic Syndrome
/ genetics
Osteochondrodysplasias
/ genetics
Primary Immunodeficiency Diseases
/ genetics
Pulmonary Embolism
/ genetics
Transplantation Conditioning
/ methods
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
16 06 2022
16 06 2022
Historique:
entrez:
15
6
2022
pubmed:
16
6
2022
medline:
18
6
2022
Statut:
ppublish
Résumé
Lifelong immunosuppression is required for allograft survival after kidney transplantation but may not ultimately prevent allograft loss resulting from chronic rejection. We developed an approach that attempts to abrogate immune rejection and the need for post-transplantation immunosuppression in three patients with Schimke immuno-osseous dysplasia who had both T-cell immunodeficiency and renal failure. Each patient received sequential transplants of αβ T-cell-depleted and CD19 B-cell-depleted haploidentical hematopoietic stem cells and a kidney from the same donor. Full donor hematopoietic chimerism and functional ex vivo T-cell tolerance was achieved, and the patients continued to have normal renal function without immunosuppression at 22 to 34 months after kidney transplantation. (Funded by the Kruzn for a Kure Foundation.).
Identifiants
pubmed: 35704481
doi: 10.1056/NEJMoa2117028
pmc: PMC10545450
mid: NIHMS1932490
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2295-2302Subventions
Organisme : NIAMS NIH HHS
ID : T32 AR050942
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2022 Massachusetts Medical Society.
Références
Mol Ther. 2016 Apr;24(4):823-31
pubmed: 26708005
J Histochem Cytochem. 2015 Jan;63(1):32-44
pubmed: 25319549
Am J Transplant. 2014 Jul;14(7):1599-611
pubmed: 24903438
Am J Transplant. 2019 Feb;19(2):475-487
pubmed: 29900661
Nat Genet. 2002 Feb;30(2):215-20
pubmed: 11799392
Blood. 2002 May 1;99(9):3482-3
pubmed: 12001906
Blood Adv. 2017 Oct 30;1(24):2166-2175
pubmed: 29296864
Pediatr Transplant. 2009 Jun;13(4):482-9
pubmed: 18785907
Am J Med Genet A. 2013 Oct;161A(10):2609-13
pubmed: 23950031
Am J Transplant. 2021 Aug;21(8):2824-2832
pubmed: 33346917
Sci Transl Med. 2020 Jan 29;12(528):
pubmed: 31996467
Crit Rev Biochem Mol Biol. 2017 Dec;52(6):696-714
pubmed: 28954549
Clin Lab. 2019 Sep 1;65(9):
pubmed: 31532093
J Pediatr. 2000 Dec;137(6):882-6
pubmed: 11113849
Blood Adv. 2022 Jan 11;6(1):281-292
pubmed: 34592755
Blood Adv. 2021 Mar 9;5(5):1333-1339
pubmed: 33656536
Transplant Cell Ther. 2021 Aug;27(8):642-649
pubmed: 34304802
Blood. 2014 Jul 31;124(5):822-6
pubmed: 24869942
Bone Marrow Transplant. 2016 May;51(5):753-4
pubmed: 26808564
Am J Med Genet A. 2012 Sep;158A(9):2204-13
pubmed: 22888040
Am J Transplant. 2019 Jun;19(6):1798-1805
pubmed: 30586230
Hum Immunol. 2018 May;79(5):272-276
pubmed: 29409743
N Engl J Med. 2008 Jan 24;358(4):353-61
pubmed: 18216355
Am J Transplant. 2020 Feb;20(2):348-354
pubmed: 31675469